Aviceda submits investigational new drug application for geographic atrophy treatment
Click Here to Manage Email Alerts
Key takeaways:
- Aviceda submitted an investigational new drug application and a fast track designation application to the FDA for AVD-104.
- Positive safety results may support the initiation of phase 2 human trials.
Aviceda Therapeutics submitted an investigational new drug application to the FDA for AVD-104 for the treatment of geographic atrophy secondary to age-related macular degeneration.
The submission is supported by positive safety data for multiple doses of AVD-104 (glycan-coated nanoparticle) across IND-enabling Good Laboratory Practice toxicity studies, including dose-range finding studies in non-human primates and rabbits, according to a press release. The company is aiming to initiate phase 2 human clinical trials of the intravitreal nanoparticle.
Image: Adobe Stock
Additionally, Aviceda submitted a fast track designation application to the FDA for AVD-104.
“With only one currently approved therapy for the treatment of GA, there is still a significant unmet medical need for patients with this condition,” Mohamed Genead, MD, co-founder, CEO and president of Aviceda, said in the release. “This IND application brings us a step closer to bringing a new and differentiated treatment option for disease modification of the key underlying pathobiology of AMD via the modulation of immune and complement dysfunction.”
Read more about
Click Here to Manage Email Alerts